Piper reiterates Overweight on Teladoc after study on avoidable ED visits$TDOCIn a study published last week, Premier identified 4.3M, or 18%, of emergency department visits by chronically ill patients that could have been avoided, but instead cost the system $8.3B, Piper Jaffray analyst Sean Wieland tells investors in a research note. The analyst believes this data point "attests to the need for increased access to care at lower costs, which can be addressed by telemedicine." He reiterates an Overweight rating on Teladoc with an $88 price target. Further reduction of barriers to access "would be another feather in the cap for the telemedicine industry," says Wieland.Read more at: (source)https://thefly.com/landingPage...* This stock has been on our trading list for a while now. Will continue to look for trades in this name. * $TDOC, Teladoc Health, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.